Gilead Sciences, Inc. - 10-Q Summary (Period Ended Sept 30, 2004)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2004, for Gilead Sciences, Inc., a biopharmaceutical company focused on anti-infectives. The company markets products for HIV (Viread, Emtriva, Truvada), Hepatitis B (Hepsera), and fungal infections (AmBisome). All share and per-share data reflect a two-for-one stock split effective August 12, 2004.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2004 | Nine Months Ended Sept 30, 2004 |
|---|---|---|
| Total Revenues | $326.2 million | $955.0 million |
| Net Income | $113.2 million | $339.1 million |
| Diluted EPS | $0.25 | $0.74 |
| Operating Cash Flow | N/A (Quarterly) | $387.3 million |
| Cash & Marketable Securities | $1,148.4 million (Total) | N/A |
| Product Gross Margin | 86.9% | 86.7% |
| Convertible Senior Debt | $345.0 million | $345.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 63% year-over-year for the quarter and 58% for the nine-month period, driven primarily by an 88% increase in HIV product sales (Viread, Emtriva, Truvada).
- Profitability: The company reported a net income of $113.2 million for the quarter, compared to $73.1 million in the prior year quarter. This contrasts with a net loss of $264.6 million for the nine months ended Sept 30, 2003, which included a $488.6 million in-process R&D charge from the Triangle Pharmaceuticals acquisition.
- Product Mix: HIV products accounted for 73% of total product sales in Q3 2004, up from 63% in Q3 2003. Truvada, launched in August 2004, generated $18.2 million in sales in its first quarter.
- AmBisome: Sales declined 3% in the quarter due to pricing pressures and competition, despite a 3% volume increase.
- One-Time Gains: The nine-month 2004 results included a $20.6 million gain on the revaluation of EyeTech warrants and a $2.3 million gain from the sale of EyeTech stock.
Guidance, Outlook, and Risks
- 2004 Guidance:
- HIV Franchise Sales: Expected to be between $870 million and $890 million for the full year.
- AmBisome Sales: Expected to be between $195 million and $205 million for the full year.
- R&D Expenses: Projected at $210 million to $220 million for the full year.
- SG&A Expenses: Projected at $300 million to $310 million for the full year.
- Effective Tax Rate: Expected to be 31% to 32% for the full year.
- Debt Redemption: The company announced the redemption of its $345 million 2% convertible senior notes in November 2004. A non-operating charge of approximately $7.4 million is expected in Q4 2004.
- New Collaboration: Entered a license agreement with Genelabs Technologies for Hepatitis C research, involving an $8.0 million upfront fee and $3.6 million annual funding.
- Risks: Key risks include dependence on HIV products and AmBisome, competition from larger pharmaceutical companies (e.g., GSK, Merck, Pfizer), pricing pressures in Europe, and potential delays in regulatory approvals for new products like Truvada in the EU.
Investor Verification Checklist
- Debt Conversion: Verify the impact of the $345 million convertible note redemption and the associated $7.4 million Q4 charge on year-end earnings.
- Truvada Adoption: Monitor the rate at which patients switch from Viread/Emtriva to the fixed-dose Truvada combination, as this affects product mix and future revenue growth.
- European Pricing: Assess the impact of continued price reductions and reimbursement delays in European markets (specifically Greece, Spain, Portugal, Italy) on gross margins and cash collection.
- R&D Pipeline: Review the status of discontinued compounds (GS 7340, GS 9005) and the progress of the new Genelabs Hepatitis C collaboration.
- Stock-Based Compensation: Note that the company currently uses APB 25; verify the potential impact of the proposed FAS 123R standard (effective 2005) on future reported earnings.